NEOS THERAPEUTICS INC. overview

$100M revenue specialty pharmaceutical company on an accelerated path to profitability [1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth P. Hecht and Gerald McLaughlin have joined the Aytu BioPharma board of directors ENGLEWOOD, CO / ACCESSWIRE / March 22, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced...

...

Thinking about buying stock in Neos Therapeutics, Oriental Culture, Sino-Global Shipping, Bank of America, or Can Fite Biopharma? PR Newswire NEW YORK, March 18, 2021 NEW YORK , March 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, OCG, SINO, BAC, and CANF. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. NEOS:...

...

- Record date for each Special Meeting of Stockholders is February 5, 2021 - - Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. - ENGLEWOOD, CO and GRAND PRAIRIE, TX / ACCESSWIRE / February 10, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Neos Therapeutics, Inc. - NEOS PR Newswire NEW YORK, Jan. 28, 2021 NEW YORK , Jan. 28, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating Neos Therapeutics, Inc. ("NEOS" or the "Company")...

...

NEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Neos Therapeutics, Inc. - NEOS PR Newswire NEW ORLEANS, Dec. 16, 2020 NEW ORLEANS , Dec. 16, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Neos Therapeutics, Inc. (NasdaqGS: NEOS) to Aytu BioScience, Inc....